Cargando…
A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb–IV non-small-cell lung cancer who failed first-line treatment
Response rate and toxicity of second-line therapy with docetaxel (75 mg m(−2)) or docetaxel, irinotecan, and lenogastrim (60 mg m(−2), 200 mg m(−2), and 150 μg m(−2) day(−1), respectively) were compared in 108 patients with stage IIIb–IV non-small-cell lung cancer. Addition of irinotecan to docetaxe...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2005
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361740/ https://www.ncbi.nlm.nih.gov/pubmed/15597104 http://dx.doi.org/10.1038/sj.bjc.6602268 |